A share price of Blueprint Medicines Corp [BPMC] is currently trading at $103.36, up 18.22%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BPMC shares have gain 16.99% over the last week, with a monthly amount glided 8.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on November 14, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $126. Previously, UBS started tracking the stock with Neutral rating on October 24, 2024, and set its price target to $88. On May 14, 2024, Stephens initiated with a Overweight rating and assigned a price target of $140 on the stock. Leerink Partners upgraded its rating to a Market Perform and increased its price target to $97 on May 06, 2024. Oppenheimer upgraded its rating to a Outperform but $85 remained the price target by the analyst firm on October 27, 2023. Needham reiterated a Buy rating for this stock on August 21, 2023, and upped its price target to $66. In a note dated July 31, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $55 to $82.
Blueprint Medicines Corp experienced fluctuations in its stock price throughout the past year between $72.24 and $121.90. Currently, Wall Street analysts expect the stock to reach $122.6 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $103.36 at the most recent close of the market. An investor can expect a potential return of 18.61% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
Trailing Twelve Months sales for Blueprint Medicines Corp [NASDAQ:BPMC] were 434.41M which represents 126.61% growth. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.64%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.48 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 94.46 points at the first support level, and at 85.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 108.04, and for the 2nd resistance point, it is at 112.71.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Blueprint Medicines Corp [NASDAQ:BPMC] is 3.32. Also, the Quick Ratio is 3.27, while the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 15.11, the price to book ratio is 20.94.
Transactions by insiders
Recent insider trading involved Albers Jeffrey W., Director, that happened on Dec 19 ’24 when 15000.0 shares were sold. CHIEF OPERATING OFFICER, Rossi Christina completed a deal on Dec 18 ’24 to sell 2274.0 shares. Meanwhile, Director Albers Jeffrey W. bought 15000.0 shares on Dec 19 ’24.
